Management of Helicobacter pylori-related disorders

Area of Science:

• Gastroenterology and Infectious Diseases
• Microbiology and Immunology

Background:

• The discovery of Helicobacter pylori (H. pylori) has transformed the treatment of chronic gastrointestinal disorders, enabling the cure of peptic ulcer disease.
• National Institutes of Health (NIH) and Maastricht conferences have established guidelines for H. pylori eradication therapy, evolving over time.
• H. pylori infection is a significant factor in various gastrointestinal conditions, including ulcers, MALT lymphoma, gastritis, and post-gastric surgery complications.

Purpose of the Study:

• To review the updated guidelines for H. pylori eradication therapy.
• To identify the recommended therapeutic regimens for H. pylori infection.
• To assess the efficacy of current treatment strategies for H. pylori eradication.

Main Methods:

• Review of consensus conference guidelines (NIH 1994, Maastricht recent conference).
• Analysis of recommended H. pylori eradication therapies.
• Evaluation of treatment regimens, focusing on proton-pump inhibitor-based triple therapy.

Main Results:

• Updated guidelines strongly recommend H. pylori eradication for duodenal/gastric ulcers, MALT lymphoma, severe gastritis, and post-gastric cancer resection.
• Treatment is also suggested for functional dyspepsia, family history of gastric cancer, long-term PPI use, NSAID treatment, and post-gastric surgery.
• Proton-pump inhibitor-based triple therapy (PPI + clarithromycin/nitroimidazole + amoxicillin) is the current best treatment, achieving 85-95% cure rates in one week.

Conclusions:

• H. pylori eradication is crucial for managing several gastrointestinal conditions.
• Proton-pump inhibitor-based triple therapy is a highly effective and recommended treatment regimen.
• Further research may be needed to solidify recommendations for certain patient groups lacking hard scientific evidence.